- Home
- EWTX vs AMN Comparison
EWTX vs AMN Comparison
Compare EWTX & AMN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EWTX
- AMN
- Stock Information
- Founded
- EWTX 2017
- AMN 1985
- Country
- EWTX United States
- AMN United States
- Employees
- EWTX N/A
- AMN N/A
- Industry
- EWTX Biotechnology: Pharmaceutical Preparations
- AMN Assisted Living Services
- Sector
- EWTX Health Care
- AMN Health Care
- Exchange
- EWTX Nasdaq
- AMN Nasdaq
- Market Cap
- EWTX 1.2B
- AMN 1.0B
- IPO Year
- EWTX 2021
- AMN 2001
- Fundamental
- Price
- EWTX $14.30
- AMN $21.92
- Analyst Decision
- EWTX Buy
- AMN Hold
- Analyst Count
- EWTX 8
- AMN 8
- Target Price
- EWTX $39.63
- AMN $31.92
- AVG Volume (30 Days)
- EWTX 932.9K
- AMN 563.6K
- Earning Date
- EWTX 08-07-2025
- AMN 08-07-2025
- Dividend Yield
- EWTX N/A
- AMN N/A
- EPS Growth
- EWTX N/A
- AMN N/A
- EPS
- EWTX N/A
- AMN N/A
- Revenue
- EWTX N/A
- AMN $2,852,436,000.00
- Revenue This Year
- EWTX N/A
- AMN N/A
- Revenue Next Year
- EWTX N/A
- AMN $2.05
- P/E Ratio
- EWTX N/A
- AMN N/A
- Revenue Growth
- EWTX N/A
- AMN N/A
- 52 Week Low
- EWTX $10.60
- AMN $17.45
- 52 Week High
- EWTX $38.12
- AMN $70.07
- Technical
- Relative Strength Index (RSI)
- EWTX 41.90
- AMN 54.51
- Support Level
- EWTX $14.87
- AMN $21.06
- Resistance Level
- EWTX $15.68
- AMN $20.74
- Average True Range (ATR)
- EWTX 0.67
- AMN 0.75
- MACD
- EWTX -0.02
- AMN 0.10
- Stochastic Oscillator
- EWTX 15.25
- AMN 75.58
About EWTX Edgewise Therapeutics Inc.
Edgewise Therapeutics Inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of treatments for severe, rare muscle disorders. It is developing orally bioavailable, small molecule therapies for musculoskeletal diseases. The company's product candidates are Sevasemten and EDG-7500. Sevasemten is an orally administered small molecule designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy (Duchenne) and Becker muscular dystrophy (Becker). The company is currently studying Sevasemten in Phase 2 trials, which are being held in the U.S. and Israel and in certain countries in Europe and Australasia.
About AMN AMN Healthcare Services Inc
AMN Healthcare Services Inc provides healthcare workforce solutions and staffing services in the United States. Its comprehensive suite of talent solutions provides management, staffing, recruitment, language services, technology, predictive and market analytics, and related services to build and manage all or parts of the clients' healthcare workforce needs. Its reportable segments are; nurse and allied solutions, physician and leadership solutions, and technology and workforce solutions. A majority of its revenue is generated from the nurse and allied solutions segment which includes the company's travel nurse staffing, labor disruption staffing, local staffing, international nurse permanent placement, and allied staffing (including revenue cycle solutions) businesses.